COVID-19 monoclonal antibody treatment impact on symptoms and post-COVID conditions among high-risk patients at a Federally Qualified Health Center

Table 4 Tests of association between TTI and outcomes at D28+ survey (N = 409)

Pearson’s Chi-squared tests performed for categorical outcomes; 2-sample independent t-tests performed for continuous outcomes. Significance level (alpha) of 0.05 for Pearson’s Chi-squared tests. Bonferroni correction used for 8 independent 2-sample t-tests—significance level (alpha) of 0.00625
Symptom count categories defined by total number of symptoms at Day 28 Survey (0, 1–2, 3–4, or 5–20)
Symptom severity categories defined by total number of moderate/severe symptoms at Day 28 Survey (0, 1, 2, ≥ 3)
Time to infusion defined as the time between symptom onset and mAb infusion. Treated as a binary variable with groups: 1–6 days (n = 203) vs 7–10 days (n = 206)
Original N = 411; tests exclude 2 patients with outlier times to infusion
PHQ-2 Patient Health Questionnaire-2, PROMIS-29 Patient-Reported Outcomes Measurement Information System-29, TTI time to mAb infusion
^aP-value for Pearson's Chi-squared test with Yates' continuity correction
^bP-value from Welch’s t-test due to unequal variances. Otherwise, Student’s t-test (assumes equal variances) performed

ISSN: 1471-2334